$30.49 Million in Sales Expected for LeMaitre Vascular Inc (NASDAQ:LMAT) This Quarter

Share on StockTwits

Equities research analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to announce sales of $30.49 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for LeMaitre Vascular’s earnings, with the lowest sales estimate coming in at $30.47 million and the highest estimate coming in at $30.51 million. LeMaitre Vascular reported sales of $28.39 million during the same quarter last year, which indicates a positive year over year growth rate of 7.4%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 18th.

On average, analysts expect that LeMaitre Vascular will report full year sales of $117.57 million for the current year, with estimates ranging from $117.53 million to $117.60 million. For the next year, analysts forecast that the firm will post sales of $129.66 million, with estimates ranging from $128.70 million to $130.25 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, October 23rd. The medical instruments supplier reported $0.25 EPS for the quarter, beating the consensus estimate of $0.21 by $0.04. The business had revenue of $29.10 million during the quarter, compared to the consensus estimate of $28.15 million. LeMaitre Vascular had a net margin of 16.76% and a return on equity of 13.38%. The company’s revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 earnings per share.

Several brokerages have recently issued reports on LMAT. ValuEngine downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, October 7th. BidaskClub upgraded shares of LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 27th. First Analysis downgraded shares of LeMaitre Vascular from a “strong-buy” rating to an “outperform” rating and upped their price target for the stock from $37.00 to $40.00 in a report on Thursday, October 24th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $40.00 price target for the company in a report on Saturday, October 26th. Finally, Lake Street Capital upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Thursday, October 24th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.25.

In related news, CEO George W. Lemaitre sold 4,891 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $35.03, for a total value of $171,331.73. Following the sale, the chief executive officer now owns 3,135,398 shares of the company’s stock, valued at $109,832,991.94. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David B. Roberts sold 12,202 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $35.29, for a total transaction of $430,608.58. Following the completion of the sale, the director now directly owns 35,226 shares in the company, valued at approximately $1,243,125.54. The disclosure for this sale can be found here. Insiders have sold 237,435 shares of company stock valued at $8,408,790 over the last quarter. Company insiders own 19.60% of the company’s stock.

Several institutional investors have recently modified their holdings of LMAT. Russell Investments Group Ltd. grew its stake in shares of LeMaitre Vascular by 92.3% in the third quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock worth $12,333,000 after purchasing an additional 173,214 shares during the last quarter. Copeland Capital Management LLC grew its stake in shares of LeMaitre Vascular by 38.7% in the third quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock worth $18,327,000 after purchasing an additional 149,642 shares during the last quarter. GW&K Investment Management LLC bought a new stake in shares of LeMaitre Vascular in the second quarter worth $3,734,000. Morgan Stanley grew its stake in shares of LeMaitre Vascular by 151.7% in the second quarter. Morgan Stanley now owns 202,672 shares of the medical instruments supplier’s stock worth $5,671,000 after purchasing an additional 122,152 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of LeMaitre Vascular in the second quarter worth $2,612,000. 79.17% of the stock is currently owned by institutional investors.

Shares of NASDAQ:LMAT opened at $35.37 on Tuesday. The company has a fifty day moving average of $34.63 and a 200-day moving average of $31.34. The company has a market capitalization of $711.09 million, a PE ratio of 42.11, a price-to-earnings-growth ratio of 4.02 and a beta of 1.21. LeMaitre Vascular has a 52-week low of $21.79 and a 52-week high of $37.35.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Wednesday, November 20th will be issued a dividend of $0.085 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $0.34 annualized dividend and a dividend yield of 0.96%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Story: What are convertible shares? 

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.